Heidelberg Pharma AG
XETRA:HPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Heidelberg Pharma AG
XETRA:HPHA
|
DE |
|
K
|
Kinder Morgan Inc
F:2KD
|
US |
|
D
|
Dollar Tree Inc
XMUN:DT3
|
US |
|
C
|
Cintas Corp
DUS:CIT
|
US |
|
S
|
Sekisui House Ltd
XMUN:SPH1
|
JP |
|
Barnes & Noble Education Inc
F:2BN0
|
US |
|
Chemung Financial Corp
NASDAQ:CHMG
|
US |
|
Castle Biosciences Inc
NASDAQ:CSTL
|
US |
|
Core & Main Inc
NYSE:CNM
|
US |
|
E
|
Experian PLC
XMUN:J2B
|
IE |
|
M
|
MS&AD Insurance Group Holdings Inc
XBER:59M
|
JP |
|
O
|
Omnicell Inc
F:OC9
|
US |
|
United Microelectronics Corp
NYSE:UMC
|
TW |
Wall St Price Targets
HPHA Price Targets Summary
Heidelberg Pharma AG
According to Wall Street analysts, the average 1-year price target for HPHA is 5.61 EUR with a low forecast of 5.56 EUR and a high forecast of 5.78 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is HPHA's stock price target?
Price Target
5.61
EUR
According to Wall Street analysts, the average 1-year price target for HPHA is 5.61 EUR with a low forecast of 5.56 EUR and a high forecast of 5.78 EUR.
What is the Revenue forecast for Heidelberg Pharma AG?
Projected CAGR
202%
Over the last 9 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 2 years is 202%.
What is the Gross Profit forecast for Heidelberg Pharma AG?
Projected CAGR
26%
Over the last 9 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 5 years is 26%.
